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right pleural effusion (Fig. 1). CA-125 was greater than 2500 U/mL.
She was referred to gynecologic oncology for suspicion of ovarian can-
cer. The patient initially underwent video-assisted thoracic surgery
(VATS) to rule out intrathoracic solid tumor. Cytology was suspicious
for malignancy, but there was no gross evidence of disease, and pleural
biopsies were benign. At laparotomy, the patient was found to have bi-
lateral ovarian masses measuring 12 cm on the left and 20 cm on the
right, diffuse seromucinous tumor implants on thebilateral diaphragms,
paracolic gutters, bladder serosa, uterine serosa, and enlarged pelvic
and paraaortic nodes. Frozen section pathology of one of the
ovarian masses was read as borderline serous ovarian tumor with
micropapillary features. The patient underwent a total abdominal hys-
terectomy, bilateral salpingo-ophorectomy, omentectomy, low anterior1. Introduction
An estimated 4100 women will die from cervical cancer in the
United States in 2015, the majority having advanced primary or recur-
rent disease (Cervical Cancaer, n.d.). Much attention has been paid in re-
cent years to the prevention of cervical cancer and fertility-sparing
therapy. While these ﬁndings represent huge improvements in clinical
outcomes, the treatment of metastatic cervical cancer remains a clinical
dilemma, with limited options. Metastatic cervical cancer has long been
viewed as a diagnosis for which there is no cure. The 5-year survival
rates are 16% for stage IVA and 15% for stage IVB carcinoma (Chiantera
et al., 2014). For advanced disease with isolated metastases, patients
may be candidates for surgical resection. However, there is no evidence
showing any beneﬁt to surgery for patients with diffuse metastasis, and
overall survival is poor for these patients. We report here a case of met-
astatic cervical adenocarcinoma treatedwith primary debulking surgery
for presumptive ovarian carcinoma with beneﬁcial survival outcome.
2. Case report
A 41-year-old G2P0020 woman presented with bloating, abdominal
pain, and a progressive 20-lb. weight loss. A computed tomography (CT)ent of SurgeryMemorial Sloan
Y 10065, USA.
. This is an open access article underresection of the rectum with end-to-end anastomosis, bilateral dia-
phragm peritonectomy, and complete gross tumor debulking. Final pa-
thology was consistent with stage IVB, high-grade endocervical
adenocarcinoma. Postoperatively, she received 6 cycles of cisplatin/pac-
litaxel chemotherapy. She remains without evidence of disease 30
months after surgery (Figs. 2 and 3).3. Discussion
Treatment for stage IVA and IVB cervical carcinoma typically entails
palliative chemotherapy. Treatment options include paclitaxel/cisplatin
with bevacizumab, paclitaxel/cisplatin, cisplatin/gemcitabine, cisplatin/
topotecan, vinorelbine, or ifosfamide (Scratchard et al., 2012; Eskander
and Tewari, 2014). Gynecologic Oncology Group (GOG) trial 204—a
phase 3 trial for patientswithmetastatic, recurrent or persistent cervical
cancer—randomized patients to four cisplatin-containing doublet com-
binations. Progression-free survival (PFS) was 5.8 months for cisplatin/
paclitaxel, 4.7 months for cisplatin/topotecan, 4.6 months for cisplatin/
gemcitabine, and 4 months for cisplatin/vinorelbine (Scratchard et al.,
2012; Eskander and Tewari, 2014). Overall survival (OS) was 12.9
months for cisplatin/paclitaxel, 10.3 months for cisplatin/topotecan,
10.3 months for cisplatin/gemcitabine, and 10 months for cisplatin/
vinorelbine (Scratchard et al., 2012; Eskander and Tewari, 2014).
More recently, GOG 240 demonstrated a 3.7-month improvement in
OS with the addition of bevacizumab to cisplatin/paclitaxel or
topotecan/paclitaxel chemotherapy (17 vs 13.3 months) (Tewari et al.,
2014). Of note, our patient did not receive bevacizumab as she wasthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Preoperative computed tomography scan showing pelvic mass (arrow). Fig. 3. Postoperative computed tomography scan at 30 months postoperatively.
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associated with more favorable responses to platinum-based chemo-
therapeutic agents include higher performance status, lack of pelvic dis-
ease, lack of previous radiation, longer intervals to recurrence, and non-
African American race; however, overall response rates are low (Moore
et al., 2010).
Patients with diffusely metastatic disease have historically been
treated with chemotherapy or palliative radiation.We could not identi-
fy any literature evaluating the surgical management of diffusely meta-
static disease, and reports assessing surgery in patients with metastatic
cervical cancer generally address resection of isolated recurrent disease
(Friedlander et al., 2002; Long, 2007). Recurrence is typically bulky and
in the pelvis. Patients with central pelvic recurrence and no evidence of
other metastasis are candidates for pelvic exenteration. Most recently,
5-year survival rates of 40% have been reported for these proceduresFig. 2. Postoperative computed tomography scan at 1 month postoperatively.(Chiantera et al., 2014; Westin et al., 2014). Isolated metastases outside
the pelvismost commonly occur in pelvic or para-aortic nodes (75% and
62%, respectively), followed by lung (33% to 38%), liver (33%), peritone-
um (5% to 27%), adrenal gland (14% to 16%), intestines (12%), and skin
(10%) (Friedlander et al., 2002). A case series of 21 patients evaluated
patients with isolated recurrence in the lungs (Lim et al., 2010). After
excision of pulmonary metastasis, 16 patients were alive without dis-
ease, 3 patientswere alivewith disease, and 2 patients had died second-
ary to disease after amedian follow-up of 16months. A case series of 10
patients evaluated patients who underwent excision of an isolated re-
currence in the liver (Papadia et al., 2011). Of those, 5 went on to die
secondary to disease, 4 had no evidence of disease after 1 year, and 1
was alive with recurrent disease.
Our patient's preoperative clinical picture, intraoperative ﬁndings,
and frozen section pathology were all consistent with ovarian cancer.
We cannot estimate from our literature review how frequently a clini-
cian will encounter a clinical scenario similar to ours in the setting of
stage IVB cervical cancer.While there have been somepublished reports
of metastatic cervical adenocarcinomamimicking primary ovarian can-
cer, or synchronous endocervical and ovarian primary neoplasms
(Elishaev et al., 2005; Yada-Hashimoto et al., 2003; Sun et al., 2015;
Khor et al., 2009), our patient was unique as she had no preoperative
symptoms, suggestion, or evidence of cervical disease. The patient
underwent a primary debulking surgery for presumed ovarian cancer,
with ﬁnal pathology revealing metastatic cervical adenocarcinoma.
Thirty months after surgery, she remains without evidence of disease,
a signiﬁcant improvement over both reported PFS and OS outcomes in
phase 3 chemotherapeutic trials. This suggests that in cases of cervical
adenocarcinoma with metastasis outside the pelvis, when all therapy
is thought to be ineffective and palliative in nature, perhaps in selected
cases of no bladder mucosal involvement, surgical debulking should be
considered. As it is important to achieve adequate surgical resection
margins, we consider that removing a signiﬁcant portion of (or the en-
tire) bladder for cases of mucosal involvement would be too aggressive
in the initial treatment of this disease. We are neither suggesting this
management for all stage IVB patients, nor do we believe that the pri-
mary cytoreductive approach described in this report would apply to
patients with recurrent disease or those who have received prior radio-
therapy. While our patient's course is highly unusual, it does pose a
question aboutwhether or not we should reevaluate the role of primary
25S.M. Davenport et al. / Gynecologic Oncology Reports 14 (2015) 23–25debulking for certain patients with metastatic cervical adenocarcinoma
given the improvements in chemotherapeutic efﬁcacy in this disease.
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